• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

Comprehensive Overview of 2-(aminomethyl)-5-bromo-3,4-dihydropyrimidin-4-one hydrochloride (CAS No. 2639418-85-0)

In the rapidly evolving field of pharmaceutical and chemical research, 2-(aminomethyl)-5-bromo-3,4-dihydropyrimidin-4-one hydrochloride (CAS No. 2639418-85-0) has garnered significant attention due to its unique structural properties and potential applications. This compound, often referred to in abbreviated forms such as 5-bromo dihydropyrimidinone or aminomethyl pyrimidine derivative, is a key intermediate in the synthesis of various bioactive molecules. Researchers and industry professionals are increasingly exploring its utility in drug discovery, particularly in the development of kinase inhibitors and antiviral agents.

The molecular structure of 2-(aminomethyl)-5-bromo-3,4-dihydropyrimidin-4-one hydrochloride features a brominated dihydropyrimidinone core, which is known for its versatility in medicinal chemistry. The presence of the aminomethyl group enhances its reactivity, making it a valuable building block for constructing more complex molecules. Recent studies have highlighted its role in targeting enzymes involved in inflammatory pathways, aligning with the growing interest in anti-inflammatory drug development and immune modulation.

One of the most frequently asked questions in online searches is, "What are the applications of brominated pyrimidine derivatives in drug discovery?" This compound addresses this query by serving as a precursor for molecules that interact with nucleic acids and proteins. Its 5-bromo substituent is particularly noteworthy, as it can participate in cross-coupling reactions, a topic of high relevance in green chemistry and sustainable synthesis. These attributes make it a focal point for discussions on efficient synthetic routes and catalyst optimization.

Another trending topic in the scientific community is the exploration of small molecule therapeutics for rare diseases. 2-(aminomethyl)-5-bromo-3,4-dihydropyrimidin-4-one hydrochloride has shown promise in this area due to its ability to modulate specific biological targets. For instance, its derivatives are being investigated for their potential in treating neurodegenerative disorders, a field that has seen a surge in public interest. Searches like "pyrimidine-based neuroprotective agents" reflect this growing curiosity.

From a technical standpoint, the compound’s hydrochloride salt form improves its solubility, a critical factor in formulation development. This property is often highlighted in forums discussing drug delivery systems and bioavailability enhancement. Additionally, its stability under various pH conditions makes it a reliable candidate for high-throughput screening assays, a method widely used in precision medicine research.

In summary, 2-(aminomethyl)-5-bromo-3,4-dihydropyrimidin-4-one hydrochloride (CAS No. 2639418-85-0) is a multifaceted compound with broad applicability in modern chemistry and pharmacology. Its relevance to drug design, sustainable synthesis, and therapeutic innovation ensures its continued prominence in both academic and industrial settings. As research progresses, this compound is likely to remain a subject of intense study and discussion, particularly in contexts like structure-activity relationships and targeted therapy development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)